

Global Cancer Biomarker Testing Market - 2023-2033

<https://marketpublishers.com/r/G5AAA035C8F5EN.html>

Date: December 2025

Pages: 217

Price: US\$ 2,999.00 (Single User License)

ID: G5AAA035C8F5EN

Abstracts

The Global Cancer Biomarker Testing Market was valued at US\$ 29.83 Billion in 2023 and is anticipated to reach US\$ 96.53 Billion by 2033, at a CAGR of 0.126 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Cancer Biomarker Testing Market.

This report delivers a comprehensive overview of the Global Cancer Biomarker Testing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Cancer Biomarker Testing Market. The Global Cancer Biomarker Testing Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

Global Cancer Biomarker Testing Market Scope:

Key Players

Illumina, Inc.

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific Inc.

Abbott

QIAGEN

Siemens Healthineers AG

Bio-Rad Laboratories, Inc

Agilent Technologies

BioMerieux

Foundation Medicine, Inc.

Major Highlights

This report delivers a comprehensive overview of the Global Cancer Biomarker Testing Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Cancer Biomarker Testing Market. The Global Cancer Biomarker Testing Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions

apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Biomarker Type
- 2.4. Snippet by Technology
- 2.5. Snippet by Product Type
- 2.6. Snippet by Application
- 2.7. Snippet by Cancer Type
- 2.8. Snippet by End-User
- 2.9. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Emergence of Multi-Omics and AI-Driven Diagnostics
 - 3.1.1.2. Shift Toward Personalized and Precision Medicine
 - 3.1.1.3. Rising Global Cancer Prevalence
 - 3.1.2. Restraints
 - 3.1.2.1. High Cost of Biomarker Tests and Drug Development
 - 3.1.2.2. Stringent Regulatory and Reimbursement Challenges
 - 3.1.2.3. Data Privacy and Management Concerns
 - 3.1.3. Opportunity
 - 3.1.3.1. Development of Novel Biomarkers
 - 3.1.3.2. Integration with Digital Health and Telemedicine
 - 3.1.3.3. Expansion of Non-Invasive Testing
 - 3.1.4. Impact Analysis

4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players
 - 4.1.2. Established leaders with the largest-selling Brand
 - 4.1.3. Market leaders with established Product
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. South America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Forces Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.11. Pricing Analysis and Price Dynamics

5. GLOBAL CANCER BIOMARKER TESTING MARKET, BY BIOMARKER TYPE

- 5.1. Introduction
 - 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 5.1.2. Market Attractiveness Index By Biomarker Type
- 5.2. Genetic Biomarkers*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Protein Biomarkers
- 5.4. Others

6. GLOBAL CANCER BIOMARKER TESTING MARKET, BY TECHNOLOGY

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 6.1.2. Market Attractiveness Index By Technology
- 6.2. Omics Technologies*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

- 6.3. Imaging Technologies
- 6.4. Immunoassays
- 6.5. Next-Generation Sequencing (NGS)
- 6.6. PCR-based Techniques
- 6.7. Others

7. GLOBAL CANCER BIOMARKER TESTING MARKET, BY PRODUCT TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 7.1.2. Market Attractiveness Index By Product Type
- 7.2. Instruments*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Consumables
- 7.4. Software

8. GLOBAL CANCER BIOMARKER TESTING MARKET, BY APPLICATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 8.1.2. Market Attractiveness Index By Application
- 8.2. Diagnostics*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Drug Discovery and Development
- 8.4. Therapy Prediction and Monitoring
- 8.5. Personalized and Precision Medicine
- 8.6. Others
- 8.7. Global Cancer Biomarker Testing Market, By Cancer Type
- 8.8. Introduction
 - 8.8.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 8.8.2. Market Attractiveness Index By Cancer Type
- 8.9. Breast Cancer*
 - 8.9.1. Introduction
 - 8.9.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.10. Lung Cancer
- 8.11. Colorectal Cancer
- 8.12. Prostate Cancer

- 8.13. Cervical Cancer
- 8.14. Liver Cancer
- 8.15. Melanoma
- 8.16. Blood Cancers
- 8.17. Others

9. GLOBAL CANCER BIOMARKER TESTING MARKET, BY END-USER

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Hospitals *
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Diagnostic Laboratories
- 9.4. Biopharmaceutical and Biotechnology Companies
- 9.5. Others

10. GLOBAL CANCER BIOMARKER TESTING MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
 - 10.2.1. Introduction
 - 10.2.2. Key Region-Specific Dynamics
 - 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
 - 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
 - 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
 - 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 10.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.2.9.1. U.S.
 - 10.2.9.2. Canada
 - 10.2.9.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.9.1. Germany

10.3.9.2. U.K.

10.3.9.3. France

10.3.9.4. Spain

10.3.9.5. Italy

10.3.9.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.9.1. Brazil

10.4.9.2. Argentina

10.4.9.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.9.1. China

10.5.9.2. India

10.5.9.3. Japan

10.5.9.4. South Korea

10.5.9.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type

10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

11.1. Competitive Overview and Key Market Players

11.2. Market Share Analysis and Positioning Matrix

11.3. Strategic Partnerships, Mergers & Acquisitions

11.4. Key Developments in Product Portfolios and Innovations

11.5. Company Benchmarking

12. COMPANY PROFILES

12.1. Illumina, Inc.*

12.1.1. Company Overview

12.1.2. Product Portfolio

12.1.2.1. Product Description

12.1.2.2. Product Key Performance Indicators (KPIs)

12.1.2.3. Historic and Forecasted Product Sales

12.1.2.4. Product Sales Volume

12.1.3. Financial Overview

12.1.3.1. Company Revenue

12.1.3.2. Geographical Revenue Shares

12.1.3.3. Revenue Forecasts

12.1.4. Key Developments

12.1.4.1. Mergers & Acquisitions

12.1.4.2. Key Product Development Activities

12.1.4.3. Regulatory Approvals, etc.

12.1.5. SWOT Analysis

- 12.2. F. Hoffmann-La Roche Ltd
- 12.3. Thermo Fisher Scientific Inc.
- 12.4. Abbott
- 12.5. QIAGEN
- 12.6. Siemens Healthineers AG
- 12.7. Bio-Rad Laboratories, Inc
- 12.8. Agilent Technologies
- 12.9. BioMérieux
- 12.10. Foundation Medicine, Inc. (LIST NOT EXHAUSTIVE)

13. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 13.1. Data Collection Methods
- 13.2. Data Triangulation
- 13.3. Forecasting Techniques
- 13.4. Data Verification and Validation

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Global Cancer Biomarker Testing Market - 2023-2033

Product link: <https://marketpublishers.com/r/G5AAA035C8F5EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5AAA035C8F5EN.html>